MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Incyte Corp

Fechado

SetorSaúde

85.4 -1.83

Visão Geral

Variação de preço das ações

24h

Atual

Mín

84.88

Máximo

86.99

Indicadores-chave

By Trading Economics

Rendimento

247M

405M

Vendas

163M

1.2B

P/E

Médio do Setor

20.622

37.257

Margem de lucro

33.319

Funcionários

2,617

EBITDA

324M

582M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

-1.67% downside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.5B

17B

Abertura anterior

87.23

Fecho anterior

85.4

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de out. de 2025, 20:45 UTC

Ganhos

Costco Wholesale Sales Climb in September, Early October

8 de out. de 2025, 20:12 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 de out. de 2025, 16:39 UTC

Grandes Movimentos do Mercado

Mining Shares Rise as Gold Prices Soar

8 de out. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 de out. de 2025, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 de out. de 2025, 23:18 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Finance Acquisition Using Internal Funds

8 de out. de 2025, 23:17 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 de out. de 2025, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 de out. de 2025, 21:54 UTC

Conversa de Mercado
Ganhos

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 de out. de 2025, 21:30 UTC

Conversa de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 de out. de 2025, 21:26 UTC

Conversa de Mercado
Ganhos

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 19:15 UTC

Conversa de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 de out. de 2025, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 de out. de 2025, 18:47 UTC

Conversa de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Will Remain a Publicly Traded Co >TASK

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 de out. de 2025, 18:07 UTC

Conversa de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de out. de 2025, 15:57 UTC

Conversa de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 de out. de 2025, 15:56 UTC

Conversa de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 de out. de 2025, 15:53 UTC

Conversa de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 de out. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 de out. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

-1.67% parte inferior

Previsão para 12 meses

Média 85.71 USD  -1.67%

Máximo 115 USD

Mínimo 60 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

8

Comprar

10

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat